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RESEARCH ARTICLE
Following specific podocyte injury captopril protects against
 progressive long term renal damage [version 1; referees: 1
approved, 2 approved with reservations]
Yu S Zhou,    Ihmoda A Ihmoda, Richard G Phelps, Christopher OS Bellamy,
A Neil Turner
Centre for Inflammation Research, Renal Medicine, University of Edinburgh and Royal Infirmary, Edinburgh, EH16 4SB, UK
Abstract
Background: Angiotensin converting enzyme inhibitors (ACEi) reduce
proteinuria and preserve kidney function in proteinuric renal diseases. Their
nephroprotective effect exceeds that attributable to lowering of blood pressure
alone. This study examines the potential of ACEi to protect from progression of
injury after a highly specific injury to podocytes in a mouse model.
Methods: We created transgenic (Podo-DTR) mice in which graded specific
podocyte injury could be induced by a single injection of diphtheria toxin.
Transgenic and wild-type mice were given the ACEi captopril in drinking water,
or water alone, commencing 24h after toxin injection. Kidneys were examined
histologically at 8 weeks and injury assessed by observers blinded to
experimental group.
Results: After toxin injection, Podo-DTR mice developed acute proteinuria, and
at higher doses transient renal impairment, which subsided within 3 weeks to
be followed by a slow glomerular scarring process. Captopril treatment in
Podo-DTR line 57 after toxin injection at 5ng/g body weight reduced proteinuria
and ameliorated glomerular scarring, matrix accumulation and
glomerulosclerosis almost to baseline (toxin: 17%; toxin + ACEi 10%, p<0.04;
control 7% glomerular scarring). Podocyte counts were reduced after toxin
treatment and showed no recovery irrespective of captopril treatment (7.1 and
7.3 podocytes per glomerular cross section in water and captopril-treated
animals compared with 8.2 of wild-type controls, p<0.05).
Conclusions: Observations in Podo-DTR mice support the hypothesis that
continuing podocyte dysfunction is a key abnormality in proteinuric disease.
Our model is ideal for studying strategies to protect the kidney from progressive
injury following podocyte depletion. Demonstrable protective effects from
captopril occur, despite indiscernible preservation or restoration of podocyte
counts, at least after this degree of relatively mild injury.
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Introduction
Podocytes are terminally differentiated, highly specialised epi-
thelial cells which cover the outer surface of the glomerular base-
ment membrane and form the final barrier to protein loss during 
glomerular filtration. Podocyte dysfunction and subsequent loss 
plays a major role in the initiation and progression of glomerular 
diseases1,2. Podocyte injury is characterised by leakage of protein 
into urine, which can occur even without morphological changes 
detectable by light microscopy. The close association between dam-
aged podocytes and proteinuria is supported by the observations 
that numerous congenital causes of substantial proteinuria are due 
to mutations influencing podocyte-specific molecules such as mol-
ecules involved in the cytoskeleton3 and slit diaphragm (podocin, 
nephrin and CD2AP4–7).
Kriz and colleagues1 proposed that progressive podocyte damage 
might lead to chronic renal failure in a number of renal diseases, 
and that progression might arise because “podocyte damage dam-
ages podocytes” (directly or through loss of inter-cell support), 
leading to a vicious cycle that drives progressive glomerular injury 
and scarring8,9. If so, interventions that reduce the disruption by res-
cuing susceptible podocytes next to injured ones are potential thera-
pies to restore podocyte phenotype and therefore ameliorate renal 
damage and/or protect the kidney from progressive damage.
There is strong evidence that proteinuria reduction with angiotensin 
converting enzyme inhibitors (ACEi) and angiotensin receptor 
blockers (ARB) can arrest deterioration in renal function in pro-
teinuric kidney diseases of any aetiology, both in animal models10–13 
and in man14,15. This protection was first attributed to haemodynamic 
effects. Recent evidence suggests additional mechanisms16,17.
We developed a model of targeted podocyte injury by construct-
ing a transgenic mouse (Podo-DTR) in which the diphtheria toxin 
receptor is expressed on podocytes. Murine cells are naturally 
1000-fold less susceptible to diphtheria toxin than human cells18. 
Transgenic mice with podocytes fully susceptible to diphtheria 
toxin were made by expressing the human diphtheria toxin receptor 
(hDTR, also known as human heparin binding epidermal growth 
factor receptor, HB-EGFR) under the control of a fragment of the 
nephrin promoter that was previously shown to be expressed solely 
in podocytes when coupled to β-galactosidase19. This technique was 
first applied to hepatocytes20 but has subsequently been successfully 
applied to a number of other cell types8,21.
Unlike models of podocyte injury that involve use of toxins of 
uncertain specificity, such as adriamycin in mice22,23, puromycin 
in rats24, and possibly pamidronate toxicity and HIV infection in 
humans25, our Podo-DTR model permits a graded, specific podo-
cyte injury that can be delivered by a single injection of diphtheria 
toxin. Here we describe application of Podo-DTR to investigate the 
nephroprotective potential of ACEi in podocyte injury.
Methods
Generation of Podo-DTR mice
The HB-EGF receptor was expressed as a transgene under the con-
trol of the murine nephrin promoter. A murine 1.25kb nephrin gene 
fragment19 was generated from murine genomic DNA. Oligonucle-
otide PCR primers (MWG Oligo synthesis) for the mouse nephrin 
gene with added NotI and BamHI restriction sites (primer sequences: 
5’-ATGGCCCAGGGATTCAGGTGC-3’ and 5’-GCTTGGAC-
CCAGTGTGAACTC-3’) were used to clone the gene fragment. 
The thermal cycling protocol of the PCR machine (Thermal Cycler 
Apollo ATC201) comprised an initial denaturation step at 75°C for 
10 minutes followed by 30 cycles of 95°C for 1minute (denaturation), 
60°C for 1 minute (annealing) and 72°C for 1.5 minute (elongation). 
The final cycle consisted of a re-annealing at 72°C for 10 minutes.
This nephrin fragment was used to replace the albumin promoter 
in the pMS7 plasmid, which was kindly donated by Dr. Saito20. 
The resulting plasmid consisted of the murine nephrin promoter- 
fragment and the human HB-EGF cDNA19. Expression driven by 
this nephrin promoter fragment was shown by Moeller et al. (2002) 
to achieve podocyte specific expression in kidneys without detect-
able expression outside the kidney by chemiluminescence assay.
Transgenic mice were generated by male pronuclear microinjection 
of murine fertilized ova derived from B6CBAF1 mice with the lin-
earised pIN plasmid (Figure 1). These mice originated from Harlan 
UK, and were offspring of a cross between the C57BL/6JolaHsd 
inbred female and the CBA/CaOlaHsd inbred male.
Transgenic offspring were identified by PCR analysis of ear notch 
DNA using the following primers: 5’-GGA AGA GAG AAG GGC 
GAG TT-3’ and 5’-GGG TCC ATG GTG ATA CAA GG-3’ for a 
243bp nephrin gene/intron product; and 5’-GGT GGT GCT GAA 
GCT CTT TC-3’ and 5’-GCT TGT GGC TTG GAG GAT AA-3’ for 
a human HB-EGF gene product. Thermal Cycler Apollo ATC201 
PCR machine was used with the same thermal cycling protocol as 
described above except for the annealing temperature (set to 50°C 
for 1 minute per cycle).
All animal studies conformed to local ethical guidelines and the 
Home Office (UK) Animals Scientific Procedures Act (1986) and 
were approved by the University of Edinburgh Ethical Review 
Committee (Ethical Review Number PL23-07). Mice were housed 
in laboratory cages (n=1–6) in a room with 12:12 hour light-dark 
cycle and allowed free access to standard dry pellet diet and water 
(unless otherwise specified) in accordance with the institutional 
guidelines.
Characterisation of the model
Podo-DTR mice and wild-type littermates as controls were injected 
with a single dose of diphtheria toxin (DT) (Product no. 150, Lot 
15023A1; List Biological Laboratories Inc., California, USA) rang-
ing from 0.1–166ng/g body weight (bw). At various time points, 
urine and blood samples were collected for albuminuria and cre-
atinine, and urea measurement respectively. Animals were sacri-
ficed (aged 7 to 11 months) by intraperitoneal injection of terminal 
anaesthesia (1mg/ml medetomidine (Dormitor) (Ref. VD DOM02, 
made by Orion Pharma, supplied by Henry Schein Medical) and 
100mg/ml ketamine (Vetalar) (Ref. PD VET10, made by Pfizer, 
supplied by Henry Schein Medical) at approximately 0.1ml/10g of 
body weight and their kidneys analysed histologically.
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ACEi protection experiment
Groups of 16 transgenic (Tg) mice and eight wild-type (WT) litter-
mates were given captopril (200mg/L) (Product no. C4042, Sigma 
Aldrich, UK) in their drinking water or placebo (water alone) 24h 
after a single intraperitoneal (i.p.) injection of diphtheria toxin at 
5ng/g bw (Product no. 150, Lot 15023A1; List Biological Labora-
tories Inc., California, USA). The size of the experimental group 
was based on a power calculation in order to have 80% power to 
detect a histological score difference of 1 on a 5 point scale with 
p≤0.05, assuming SD for score is 1.
Animals of both sexes (1:3 female to male ratio) aged 3 to 12 months 
(mean: 7.4, median: 8 months) were allocated to three groups: 
•   Tg DT+H2O received water alone;
•   Tg DT+ACEi were treated with captopril;
•    WT DT+ACEi were wild-type littermate controls treated 
with captopril.
Urine samples were collected over 24h in metabolic cages at days 0, 
14, 42, 49 and 56 and analysed for albumin:creatinine ratio (ACR). 
Systolic blood pressures were measured by tail cuff plethysmogra-
phy on trained conscious animals during week 7 after toxin injec-
tion, and the mean of 3–4 measurements was recorded for each 
animal. Untreated Podo-DTR mice (n=5) (transgenic not given 
diphtheria toxin or captopril) were also included to assess baseline 
blood pressure.
Terminal blood samples were collected at week 8 from intraperi-
toneally anaesthetised animals (injected with medetomidine and 
ketamine).
Kidneys from each animal were bisected sagitally and fixed as 
required by overnight incubation at 4°C in fixative (10% neutral 
formalin (VWR Brand P/L-Chemicals), Methyl-Carnoy fixative 
(60% absolute methanol, 30% chloroform, 10% glacial acetic 
acid (Fisher Scientific UK Ltd), or Karnovsky’s glutaraldehyde 
(700mOsm) (Ref. G5882-100ml, Sigma Aldrich) or snap frozen 
in liquid nitrogen. For light microscopy, formalin-fixed samples 
were embedded in paraffin-wax and 2µm sections cut and stained 
with haematoxylin and eosin (H&E) or periodic acid-Schiff (PAS) 
(Fisher Scientific UK Ltd).
Urine and blood analysis
Urine and serum creatinine concentrations were measured using 
the creatinase reaction, with the exception of the first cohort of 
the model evaluation studies where Jaffe reaction was used (for 
the Podo-DTR line 47 given 1ng/g DT). Serum urea was meas-
ured using the urease reaction (Alpha Laboratory Ltd, Poole, UK). 
An immunoturbidimetric assay was developed to measure uri-
nary mouse albumin concentration using a commercial diagnostic 
Microalbumin Kit (Olympus Diagnostic Ltd, Watford, UK) stand-
ardised against purified mouse albumin (Sigma Chemical Co. 
Poole, UK). All the assays were adapted for use on a Cobas Fara 
centrifugal analyser (Roche diagnostics Ltd, Welwyn Garden City, 
UK) according to manufacturer’s instructions.
Figure 1. (a) Schematic representation of the transgene. Human diphtheria toxin receptor (DTR), or human heparin binding-epidermal growth 
factor (HB-EGF) receptor, is expressed as a transgene under the control of the murine nephrin promoter. (b) Agarose gel showing positive 
bands for the PCR products of a 243bp fragment from podocyte nephrin promoter and rabbit-ß-globin intron of transgenic Podo-DTR mice. 
M, marker Hae ladder; Tg, trasgenic; WT, wild type.
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Glomerulosclerosis score
Sclerosis was defined as collapse and/or obliteration of glomerular 
capillary tuft accompanied by presence of hyaline material and/or an 
increase in matrix12. Glomerulosclerosis was graded on 2µm thick 
PAS-stained sections, adopting the semi-quantitative scoring sys-
tem proposed by El Nahas et al.26. The severity of glomerulosclero-
sis was expressed on a scale of 0 to 2. The scoring system used was 
as follows: 0: normal glomerulus or no lesion; 1: <50% sclerosis; 
2: 50–100% sclerosis of glomerular tuft area. Using light micros-
copy at a magnification of x40 (Olympus CX40), 100 glomeruli per 
animal were scored for glomerulosclerosis by an observer blinded 
to experimental group.
Immunohistochemistry
Paraffin-embedded, formalin-fixed kidneys were cut at 3µm thick-
ness. After deparaffinising and hydrating, the sections were treated 
with the antigen retrieval solution Borg Decloaker RTU (Ref. 
BD1000MM Biocare Medical) for 2 minutes after reaching pressure 
according to manufacturer’s instructions. The sections were incu-
bated with rabbit polyclonal anti-Wilm’s tumour 1 (WT1) sc-192 
IgG antibody (1:50; Santa Cruz Biotechnology, Inc) for 1h at room 
temperature. Immunoperoxidase staining was performed according 
to the Vectastain ABC kit (Vector Laboratories). Diaminobenzidine 
(DAB) (Vector Laboratories, Inc Burlingame, CA) was used as the 
immunoperoxidase detection system.
Podocyte quantification and glomerular area measurement
WT-1 is a marker that specifically stains podocyte nuclei. Podo-
cytes were counted in 50 consecutive glomerular cross-sections 
per animal viewed at x40 magnification (Olympus CX40), and the 
mean podocyte per glomerulus count calculated for each animal, 
n=16 (transgenic), n=8 (wild-type).
To investigate for any change in glomerular size following treat-
ment (with diphtheria toxin and/or ACEi treatment), 50 consecutive 
glomerular cross section (GCS) per animal were measured using 
ImageJ 1.4r software on pictures taken at x10 magnification using 
QCapturePro (QImaging Micropublisher 3.3 RTV, Zeiss Axioskop, 
Germany).
Statistical analysis
Results are expressed as mean ± standard error of the mean (SEM) 
or median where specifically stated. Statistical differences between 
groups were tested by the Student t-test or Wilcoxon Rank Sum as 
appropriate (Graphpad Prism 4 version 1.0 or R www.r-project.org 
version 2.1). A p-value of <0.05 was considered to be significant.
Results
Derivation
Three transgenic lines with positive PCR results for the transgene 
(Figure 1b) were established (Podo-DTR 47, 57 and 21). Earlier 
studies in total of 10, 17 and 24 mice of Podo-DTR line 47, 57 and 
21 respectively (male and female) aged 6.5 to 9 months showed that 
two of the lines (47 and 57) were susceptible to diphtheria toxin. 
All three lines were entirely healthy and had normal glomerular 
morphology. Non-transgenic animals and also animals from line 
21 had normal glomerular morphology regardless of the dose of 
toxin received. Mice from lines 47 and 57 developed renal injury in 
response to low doses of toxin but no pathology outside the kidneys 
was detected.
Podo-DTR mice develop podocyte injury after diphtheria 
toxin injection
In dose-ranging studies, animals were injected intraperitoneally with 
diphtheria toxin at 0.1–166ng/g bw. Mice from line 47 were most 
susceptible and developed fatal acute renal injury in response to 
doses of 2.5ng/g or greater (n=3–6/group, aged 2–10 months), and a 
dose-dependent, slowly progressive (over 6 months) glomeruloscle-
rosis in response to lower doses (n=3–6/group, aged 2–6 months). 
Mice from line 57 developed only proteinuria even at doses as high 
as 20ng/g bw (n=6/group, aged 2–10 months). Mice from line 21 
were unaffected by administration of toxin despite carrying the 
transgene (n=3–6/group at 1ng and 50ng/g bw, aged 6–9 months).
Albuminuria and serum urea peak at week 2
The time course of sub-lethal toxin treatment in line 47 was: devel-
opment of proteinuria (6mg/mmol at 48h vs 2mg/mmol baseline, 
p=0.031) within days which increased in severity over 2 weeks 
(2048mg/mmol) then declined (57.6mg/mmol at 5 weeks) but 
never to baseline (12.4mg/mmol at 26 weeks (n=3–6) (Figure 2a). 
No significant albuminuria was seen in transgenic animals not 
given toxin or wild-type animals treated with diphtheria toxin 
(0.9–6.3mg/mmol) (Supplementary Table 1).
Serum urea showed a similar acute profile to ACR (Supplementary 
Table 2). Although the number of experimental animals was small 
(n=3–7), it appeared that there was an acute rise in blood urea at 
day 14 (10.9mmol/L vs 5.4mmol/L at d0), followed by temporary 
recovery at week 5 (5.1mmol/L) and then by slow deterioration 
(7.9, 8.1, 9.2mmol/L at week 6, 8 and 26 respectively).
Morphological glomerular damage is progressive
Toxin treated transgenic (Podo-DTR) mice showed a progressive 
reduction in the number of normal glomeruli with time (74% at 
6 weeks, 53% at 26 weeks, Figure 2b). At 1 month, early focal seg-
mental glomerulosclerosis (FSGS) and chronic renal damage was 
observed (Figure 3C–D). Importantly, additional glomeruli became 
morphologically abnormal even after 6 weeks post-toxin-treatment. 
In contrast, almost all of sampled glomeruli in control group ani-
mals (wild-type toxin-treated and transgenic untreated animals) 
were morphologically normal (96%) (Figure 2b).
Podocyte number falls and remains low
The number of podocytes per glomerular cross section (GCS) was 
reduced in toxin-treated susceptible animals compared to the con-
trols in Podo-DTR line 47 (6.2 at 2 weeks, 5.3 at 26 weeks vs 10.0 
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podocyte per GCS in controls, p<0.02) (Figure 4). The reduction in 
podocyte count was dose-dependent in line 57 animals. At higher 
toxin dose (20ng/g bw DT) at 14 days, the mean podocyte number 
dropped to 6.1 podocyte/GCS compared with 7.2 podocyte/GCS 
in mice treated with lower dose at 5ng/g bw toxin at week 8 ver-
sus 8.5 podocyte/GCS of Tg saline treated controls (p<0.04). 
(Supplementary Table 3).
Drug intervention study
ACEi-treatment lowered blood pressure and proteinuria
ACEi-treatment lowered systolic blood pressure in toxin-treated 
line 57 and wild-type mice from a mean of 114 to 84±1.7 and from 
114 to 73±1.9 mmHg respectively (Figure 5a).
ACEi-treatment also substantially reduced proteinuria in toxin-
treated line 57 mice, although not to the levels observed prior to 
toxin treatment, or in wild type mice (range: 0.0–6.8mg/mmol) 
Figure 4. Podocyte quantification of Podo-DTR line 47 mice at 2 
and 26 weeks after diphtheria toxin (DT) injection at 1ng/g bw. 
Podocyte numbers were significantly reduced at 2 and 26 weeks 
after toxin injection compared to the controls (6.2 and 5.3 versus 
10.0 podocyte/GCS respectively, p<0.02). bw, body weight; GCS, 
glomerular cross section; * p=0.015; ** p=0.001;♦, wild-type control 
mice injected with DT; ♦, transgenic mice injected with saline.
Figure 3. Glomerular histology of DT treated and untreated 
mice. (A) Normal glomerulus in untreated transgenic mouse. 
(B) Damaged glomerulus with abnormal morphology and vacu-
olated cytoplasm (*) from treated Podo-DTR line 47 (25ng/g bw 
DT) at D7. (C–D) Sclerosed glomeruli from treated Podo-DTR line 
57 (1ng/g bw DT) at D28 with (C) partially damaged glomerulus 
with normal morphology at 4 o’clock, with tuft/capsular adhesion in 
the area of segmental scar at 9 o’clock, and (D) almost completely 
sclerosed glomerulus. PAS staining, 40x magnification. * p=0.002; 
** p<0.0001; DT, diphtheria toxin; bw, body weight; D, day; NS, non 
significant; PAS, Periodic Acid Schiff.
Figure 2. (a) Albumin:creatinine ratio (ACR) measured in urine of 
Podo-DTR line 47 at intervals after injection with 1ng/g bw. Acute 
proteinuria was highest at week 2 (mean value 2047.9mg/mmol) 
falling to much lower levels by 5 weeks (57.6mg/mmol) and 
remaining low at 26 weeks (12.4mg/mmol). No substantial change 
was seen in control groups (0.9–6.3mg/mmol) (data not visualized). 
(b) Glomerulosclerosis score of Podo-DTR line 47 mice at 6 and 
26 weeks post DT injection at 1ng/g bw. 100 glomeruli were scored 
per animal (Uncropped gel image in Supplementary Figure 1).
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(Figure 5b). The peak level of proteinuria (at week 2) was reduced 
from 272±128mg/mmol in ACEi-treated mice compared to 
39.1±9mg/mmol in mice treated with the diphtheria toxin only, and 
was substantial at all measurement times (Figure 5b).
ACEi-treatment reduced histological damage
The proportion of glomeruli showing scarring and matrix accumu-
lation in toxin-treated line 57 mice was substantially reduced in 
ACEi-treated mice (10% vs 17%, 10%, p<0.04), almost to the lev-
els observed in wild-type control mice (7%) (Figure 6 & Figure 7).
Figure 7. Kidney histology of ACEi treated and untreated Podo-
DTR line 57 mice. (A) Cluster of 4 glomeruli with varying degree 
of scar from a Tg DT+H2O treated mouse injected with 5ng/g bw 
DT; (B) Improved glomerular histology of a Tg DT+ACEi treated 
mouse injected with 5ng/g bw DT. PAS staining, 20x magnification. 
DT, diphtheria toxin, ACEi: angiotensin converting enzyme inhibitor, 
bw: body weight; Tg, transgenic; *, p<0.02; **, p≤0.001; NS, non 
significant (p=0.33); PAS, Periodic Acid Schiff.
Figure 6. Glomerulosclerosis score of Podo-DTR line 57 mice at 
8 weeks post DT injection at 5ng/g bw +/- captopril (200mg/L). 
Glomerular scarring was reduced almost to baseline level by ACEi 
captopril (Tg DT+H2O: 17%, Tg DT+ACEi: 10%, p<0.04; wild-type 
control: 7%).
Figure 5. (a) Tail cuff blood pressure (BP) of Podo-DTR line 57 mice. 
At 7 weeks post DT injection (1ng/g bw), the BP of ACEi treated mice, 
whether Tg or WT (84 and 73mmHg respectively) were significantly 
lower (p<0.001) than the untreated groups (114mmHg). (b) Urine 
albumin:creatinine ratio (ACR) of Podo-DTR line 57 mice. At day 0, 
prior to DT injection, mice from all 3 groups had baseline level of urine 
ACR (range: 0.0–6.8mg/mmol). The DT+H2O treated group peaked 
at week 2 (271.5±128mg/mmol), the DT+ACEi treated group had 
the urinary ACR level blunted substantially (39.1±9mg/mmol). The 
long-term albuminuria was lowered in both DT+ACEi treated and 
DT+ H2O groups. The WT controls had baseline level of urine ACR 
throughout the experiment (mean range value: 3.0–4.6mg/mmol). 
DT, diphtheria toxin; ACEi, angiotensin converting enzyme inhibitor; 
Tg, transgenic; WT, wild type; bw, body weight; vs, versus; 
*, p<0.0001 vs Tg DT+H2O; #, p≤0.0001 vs Tg DT+ACEi; +, p=0.002 
vs WT DT+ACEi.
ACEi-treatment did not protect from podocyte loss
Podocyte counts at week 8 were lower in toxin-treated susceptible 
mice than wild-type controls (median podocytes per GCS was 7.1 
for Tg DT+H2O, and 8.2 for wild-type mice, p<0.05 by Wilcoxon 
Rank Sum). However, the counts in ACEi-treated, toxin-treated line 
57 mice were not significantly higher (7.3 for Tg DT+ACEi) than in 
toxin-treated line 57 mice, and were significantly lower than in wild 
type controls (10% Wilcoxon Rank Sum) (Figure 8a). These results 
suggest that ACEi-treatment was not advantageous for podocyte 
preservation in this model (Figure 8b).
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A lack of benefit of ACEi treatment for podocyte preservation contin-
ued to be apparent when podocyte counts were expressed as counts per 
unit in glomerular cross sectional area, in order to compensate for any 
change in glomerular size. Indeed, mean glomerular size measured in 
50 consecutive glomerular cross-sections using ImageJ 1.4r software 
was similar in the experimental groups irrespective of toxin-treat-
ments at 9676, 10708, and 9693µm2 in WT DT+ACEi, Tg DT+H2O 
and Tg DT+ACEi respectively, p>0.08 (Supplementary Table 4).
Discussion and conclusions
Our results demonstrate utilisation of mice engineered to be sus-
ceptible to podocyte damage to evaluate the capacity of podocyte-
protective drugs such as captopril to modulate self-perpetuating 
mechanisms of podocyte damage. Other groups have developed 
toxin receptor-mediated conditional podocyte knockout models8,27 
similar to ours, but the application of such models in drug studies 
is novel.
Our Podo-DTR mouse model has a number of advantages over 
the existing animal models. Wiggin et al. have employed similar 
technology8,27 but in rats rather than mice. A mouse model offers 
greater potential for further analysis because of the rich availability 
of mouse-specific reagents and large number of existing transgenic 
mouse lines. Moreover, breeding turnover is greater with a higher 
litter number, maintenance costs are lower and smaller volumes of 
toxins or drugs are required for studies.
Unlike the human (h) CD25 mouse model generated by Ichikawa’s 
group in Japan8,27, where only relatively short-term timepoints (up 
to four weeks) have been presented, even after low dose of LMB2 
immunotoxin treatment at 0.625ng/g bw, our Podo-DTR mice sur-
vived up to six months after 1ng/g bw DT injection in line 47. This 
allowed analysis of long-term timepoints for histological changes 
and sclerosis development.
ACEi and ARB were originally thought to effect renal protection 
via haemodynamic effects and reduced glomerular filtration pres-
sure. Although blood pressure reduction by any means has been 
shown to protect renal excretory function in proteinuric diseases28, 
this accounts for only a part of the activity of ACEi and ARB agents. 
Proposed additional mechanisms of renal protection include modu-
lation of the toxicity of filtered protein by influences upon non-
glomerular cells29: it is thought that filtered protein may be toxic to 
renal tubular cells contributing to interstitial fibrosis30.
An alternative hypothesis is that ACEi and ARB exert a beneficial 
influence on the rate of continuing podocyte damage/loss thought to 
be central to the progression of proteinuric renal diseases and devel-
opment of chronic renal failure8,9,31. There is evidence - from elegant 
work utilising genetic chimeras in which a podocyte subpopulation 
expresses the hCD25 toxin receptor and may be selectively injured - 
that podocyte injury initially focused on a subset of podocytes can 
spread to other podocytes32. The initial insult caused by the toxin 
exposure to hCD25-positive podocytes lead to cell death and mas-
sive proteinuria within 4 days, followed by a secondary wave of 
injury to podocytes lacking the toxin receptor at 6 weeks post-toxin 
administration, with foot process effacement and downregulation 
of podocyte specific markers such as nephrin, podocin and VEGF 
in conjunction with an increase of the injury marker desmin. These 
results parallel the findings of our study where additional glomeru-
lar damage and possibly further reduction in podocyte number was 
observed from up to 26 weeks after acute injury, long after the 
initial injury induced by diphtheria toxin (Figure 2b & Figure 4). 
This suggests that we may also be seeing the phenomenon of 
Figure 8. Box plots of the podocyte count (a) or podocyte count per unit glomerular cross section area (b) for Podo-DTR mice treated with 
toxin with or without ACEi compared with wild-type (toxin + ACEi treated) mice at week 8. Significance was assessed using the 10% Wilcoxon 
Rank Sum test. Tg, transgenic; WT, wild-type; ACEi, angiotensin converting enzyme inhibitor; GCS, glomerular cross section; DT, diphtheria 
toxin; NS, non significant; *, p = 0.03; **, p≤0.003.
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propagation of podocyte injury, “podocyte damage damages podo-
cytes” leading to progressive glomerular injury and scarring. This 
finding may open up the possibility that drugs that protect podo-
cytes may also be generally nephroprotective.
Any broader implication of podocyte health for renal preservation 
is important to define as many drugs employed in renal disease have 
been shown to have direct effects on podocytes. As well as ACEi 
and ARB10,16,17, direct effects on podocytes have been reported 
for: immunosuppressive drugs including corticosteroids33,34, cal-
cineurin inhibitors such as cyclosporine35 and tacrolimus36, and 
mizoribine37,38; and non-immune drugs including the endothelin 
A receptor antagonist (ETA-RA)39,40, and peroxisome proliferator-
activated receptor gamma (PPARγ) agonists41,42.
The Podo-DTR mouse model described here has advantages for 
studying podocyte rescue as it is possible - through selection of 
the dose of toxin - to produce a consistent non-lethal degree of 
podocyte-specific injury. Mild degrees of injury were shown to 
superficially heal over 8 weeks with normalisation of glomerular 
morphology observable under light microscopy and reduction of 
proteinuria, but also with continuing reduction in podocyte num-
bers and low level proteinuria. On this background we were able 
to demonstrate a benefit of captopril in arresting histopathological 
progression of glomerular damage despite a reduction in podocyte 
number. This is in contrast to studies that have shown a protective 
effect of ACEi upon podocyte number in certain settings10,17, but in 
agreement with two other chronic models of renal disease in subto-
tally nephrectomised rats13 or antibody-induced nephritic mice42.
Comparison of the change in podocyte number between studies 
is complicated by the range of indirect measurement techniques 
that have been used. Our study employed quantification of podo-
cytes per glomerular tuft in a 2D image similar to the approach of 
many other groups43–45. Another approach is to estimate the total 
number of podocytes per whole glomerulus by extrapolating a vol-
ume from a series of 2D images2, which may have some advantages 
but is elaborate, very difficult to apply to experiments with large 
numbers of animals, and assumes glomeruli have a consistent size 
and spherical shape. The best technique with which to quantify podo-
cytes is still a matter of debate, but whilst this difficulty complicates 
comparison between studies, it does not prevent conclusions from 
the comparisons made within the various studies where measure-
ments have been made using a consistent technique.
Our results suggest that protection against podocyte loss is not the 
only mechanism by which ACEi achieve long-term nephroprotec-
tion: it is likely that an influence on podocyte phenotype or function 
is also important. Our model could be used to identify or screen 
new compounds to reduce podocyte damage and preserve renal 
function.
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Supplementary Table 3.
Podocyte quantification of Podo-DTR mice treated with 20ng/g bw DT at week 2 (14d) and 5ng/g bw DT at week 8 (56d). At higher toxin 
dose (20ng/g bw DT) at 14 days, the mean podocyte number dropped to 6.1 podocyte/GCS compared with 7.2 podocyte/GCS in mice treated 
with lower dose at 5ng/g bw toxin at week 8 versus 8.5 podocyte/GCS of Tg saline treated controls (p<0.04).
Click here to access the data.
Supplementary Table 4.
Glomerular area and diameter measurements of Podo-DTR line 57 treated with 5ng/g bw DT and ±ACEi captopril (200mg/L). Glomerular 
area of 50 consecutive GCS was measured using ImageJ 1.4r software. The results showed no significant difference in mean glomerular area 
between the WT DT+ACEi, Tg DT+H2O and Tg DT+ACEi groups (group mean 9676, 10708, 9693µm2 respectively), p>0.08.
DT, Diphtheria toxin; ACEi, angiotensin converting enzyme inhibitor; GCS, glomerular cross section; WT, wild type; Tg, transgenic.
Click here to access the data.
Supplementary Figure 1.
Raw gel image for Figure 1b.
Click here to access the data.
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This is an interesting and well-presented paper that uses transgenic (Podo-DTR) mice to demonstrate (1)
that continuing podocyte dysfunction is a key abnormality in proteinuric disease and (2) following specific
podocyte injury captopril protects against progressive long-term renal damage. However there are a
number of issues with the manuscript.
Three transgenic lines with positive PCR results for the transgene were established (Podo-DTR 47,
57 and 21) by the authors two of which (47 and 57) were susceptible to the DT. However instead of
comparing the 2 lines with wild type mice, different lines are used for different experiments. The
model characterization uses mainly Line 47 but experiments using captopril are done exclusively in
Line 57. What happens to mice from Line 47 treated with captopril-does it have the same
protective effect to that seen in Line 57?
 
The authors should confirm that the DTR protein is indeed exclusively expressed in the podocyte.
 
The authors do not explain why there is such a wide spread in the ages of the mice (3-12 months)
used. Does not ageing introduce unneeded variability into the study that may confound some of the
effects seen?
 
There is variability in the doses of DT used in each experiment that makes the results difficult to
compare. For example in figure 5 for tail cuff blood pressure and urine albumin:creatine ratio 1ng/g
bw was used but for glomerulosclerosis and kidney histology studies animals were treated with
5ng/g bw.  Furthermore kidney histology for Line 57 in figure 3 uses 1ng/g bw but in figure 7 it is
5ng/g bw. Why the lack of consistency?
 
In figure 4 control mice for PodDTR line 47 are reported to have 10 podocytes/GCS whilst those for
PodDTR line 47 in figure 8 have 8.2 podocytes/GCS. Why the discrepancy between the two lines?
 
At what age were the samples taken for figure 6 and 7 and what dose of DT was used in figure 8?
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it is of an acceptable scientific standard, however I have significant reservations, as outlined
above.
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 Johannes Schlondorff
Division of Nephrology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, UK
In their manuscript, the authors adapt the use of podocyte-specific ablation using transgenic diphtheria
toxin receptor (DTR) expression to the mouse. The murine model functions similarly to the previously
described rat model of Wiggens  Using the model, the authors examine the role of ACE inhibitionet al.
(captopril) as a protective therapy. Overall, the conclusions are well supported by the experimental
results, though the experiments are neither as detailed nor as compelling as those previously published
by others. The two major conclusions of the manuscript, that podocyte depletion can lead to the initiation
of a feed-forward podocyte pathology and that ACE inhibition can slow or ameliorate this process, have
been well documented by others.
The major concerns about the interpretation of the results stem from the fact that: 1. two different
transgenic lines are used without clear side-by-side comparison of both lines for the most relevant
experiments; and 2. the animals used in the captopril experiment are mixed sex and of a very large range
of ages (3-12 months), likely leading to the large variability in the data, limiting power, and making it
difficult to lend much credence to the negative results regarding captopril’s effect on podocyte numbers.
Analysis of the data using matching for age and sex, if possible, would be of interest. Overall, the 57
transgenic lines used in the ACEi experiment show only very modest glomerular sclerosis compared to
controls (Figure 6), and the control animals in this experiment have surprisingly lower number of
podocytes per glomerulus (8.2; figure 8) compared to control animals in an earlier experiment (10.0,
figure 4). Some explanation should be provided.
 
Minor points:
Figure 3 legend refers to p values, body weight to which there are no corresponding data
presented.
 
Figure 5a: Is there a difference between the “++” and “+++”?  For figure 5b, the lines connecting the
time points should be removed. In addition, including individual values and means (as in other
figures) or at least including the n’s would be helpful.
 
Number of animals/samples should be consistently provided in the figures (eg figure 8, 5b).
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In this study, the authors established a new mouse model of inducible podocyte injury. They also showed
that ACEi treatment effectively attenuated proteinuria and glomerulosclerosis in this model. Similar to
previous reported models, this model also reproducibly develops progressive glomerulosclerosis. The
data are confirmative, but this model will be an alternative useful model for podocyte injury. Compared to
hCD25 transgenic mouse model (NEP25), podocyte injury is relatively mild. The time course of ACR in
line 47 (Figure 2a) appears to be similar to that of NEP25 injected with 0.625 ng/g BW of LMB2.
 
Generally, the study is well done, and the data are properly presented. There are only some minor
concerns.
It would be better to present HB-EGF mRNA or protein expression data. Is the transgene actually
expressed selectively in podocytes?  Is the sensitivity of toxin parallel to transgene expression
among three lines?
 
Data among three or more groups should be analyzed by ANOVA or some other methods to
reduce type 1 error. Generally, urinary ACR shows logarithmic normal distribution. These data
should be properly transformed before analysis. Figure 5b data should be analyzed by mixed effect
model or other appropriate methods.
 
In wild-type C57BL/6 mice younger than 10 months of age, glomerulosclerosis is very rare. The
wild-type control mice treated with ACEi, 7% of glomeruli showed segmental sclerosis. Is this
senile change? If so, more detailed information of mouse age would be presented, or consider
deleting aged mice from the experiment.
 
Please indicate what the bottom and top of the box and whisker represent in Figure 8.
 
The authors state that ACEi was not advantageous for podocyte preservation. I do not agree on
this statement. It is just a matter of statistical power. The protective effect by ACEi is small relatively
to the variance of podocyte number in each group.  
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